At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Ola Oluwole of Vanderbilt University Medical Center, sat down with Oncology Data Advisor to discuss two of his abstracts on prophylactic corticosteroid use for patients receiving axicabtagene ciloleucel and the role of cytokine release syndrome in the efficacy of chimeric antigen receptor (CAR) T-cell therapy.